About Us
Company Profile
Management Team
Business Model
Milestones
Contact Us
Product & Pipeline
ONIVYDE®
PEP07 (CHK1 inhibitor)
PEP08 (PRMT5:MTA inhibitor)
Investors
Fundamentals
Events & Presentations
Financial Reports
Shareholders' Meeting
News
Corporate Governance
Overview
Board of Directors
Functional Committees
Communication with Independent Directors
Major Internal Policies
Risk Management
Cyber Security
Intellectual Property Management
Sustainability
Corporate Social Responsibility
Ethical Management
Stakeholder Communication
Human Rights
Health & Safety
Careers
EN
Chinese
Home
About Us
Company Profile
Management Team
Business Model
Milestones
Contact Us
Product & Pipeline
ONIVYDE®
PEP07 (CHK1 inhibitor)
PEP08 (PRMT5:MTA inhibitor)
Investors
Fundamentals
Events & Presentations
Financial Reports
Shareholders' Meeting
News
Corporate Governance
Overview
Board of Directors
Functional Committees
Communication with Independent Directors
Major Internal Policies
Risk Management
Cyber Security
Intellectual Property Management
Sustainability
Corporate Social Responsibility
Ethical Management
Stakeholder Communication
Human Rights
Health & Safety
Careers
Language
EN
Chinese
News
Homepage
Investors
News
2021-01-05
PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021
1
2
3
